Quest Diagnostics Inc (DGX) stock
DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 12/3010% above fair value
$259.60−0.05 (-0.02%)
Close on Nov 13, 2026Market cap $28.56BP/E 25.9Yield –
Quest Diagnostics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quest Diagnostics's ebitda for the twelve months ending Sep 30, 2026 was $2.31B, up 10.4% year over year. For fiscal 2025 it was $2.13B, up 15.6% from the year before. Over ten years it grew 2.2% a year on average. The highest annual figure on record is $2.79B in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.13B | +15.6% |
| FY2024 | Dec 31, 2024 | $1.84B | +8.1% |
| FY2023 | Dec 31, 2023 | $1.70B | -8.8% |
| FY2022 | Dec 31, 2022 | $1.87B | -33.1% |
| FY2021 | Dec 31, 2021 | $2.79B | +19.6% |
| FY2020 | Dec 31, 2020 | $2.33B | +49.5% |
| FY2019 | Dec 31, 2019 | $1.56B | +10.6% |
| FY2018 | Dec 31, 2018 | $1.41B | -1.7% |
| FY2017 | Dec 31, 2017 | $1.44B | -6.0% |
| FY2016 | Dec 31, 2016 | $1.53B | -10.4% |
| FY2015 | Dec 31, 2015 | $1.70B | +31.3% |
| FY2014 | Dec 31, 2014 | $1.30B | -26.2% |
| FY2013 | Dec 31, 2013 | $1.76B | +18.1% |
| FY2012 | Dec 31, 2012 | $1.49B | +17.4% |
| FY2011 | Dec 31, 2011 | $1.27B | -17.5% |
| FY2010 | Dec 31, 2010 | $1.54B | -4.8% |
| FY2009 | Dec 31, 2009 | $1.62B | +8.7% |
| FY2008 | Dec 31, 2008 | $1.49B | +11.9% |
| FY2007 | Dec 31, 2007 | $1.33B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $626.00M | +18.6% |
| Q2 FY2026 | Jun 30, 2026 | $605.00M | +4.1% |
| Q1 FY2026 | Mar 31, 2026 | $546.00M | +12.3% |
| Q4 FY2025 | Dec 31, 2025 | $531.00M | +7.1% |
| Q3 FY2025 | Sep 30, 2025 | $528.00M | +16.0% |
| Q2 FY2025 | Jun 30, 2025 | $581.00M | +23.1% |
| Q1 FY2025 | Mar 31, 2025 | $486.00M | +16.8% |
| Q4 FY2024 | Dec 31, 2024 | $496.00M | +31.9% |
| Q3 FY2024 | Sep 30, 2024 | $455.00M | +0.4% |
| Q2 FY2024 | Jun 30, 2024 | $472.00M | +2.6% |
| Q1 FY2024 | Mar 31, 2024 | $416.00M | +1.0% |
| Q4 FY2023 | Dec 31, 2023 | $376.00M | +49.8% |
| Q3 FY2023 | Sep 30, 2023 | $453.00M | -9.4% |
| Q2 FY2023 | Jun 30, 2023 | $460.00M | -7.1% |
| Q1 FY2023 | Mar 31, 2023 | $412.00M | -33.4% |
| Q4 FY2022 | Dec 31, 2022 | $251.00M | -60.9% |
| Q3 FY2022 | Sep 30, 2022 | $500.00M | -33.6% |
| Q2 FY2022 | Jun 30, 2022 | $495.00M | -21.8% |
| Q1 FY2022 | Mar 31, 2022 | $619.00M | -18.7% |
| Q4 FY2021 | Dec 31, 2021 | $642.00M | -28.1% |
| Q3 FY2021 | Sep 30, 2021 | $753.00M | -6.7% |
| Q2 FY2021 | Jun 30, 2021 | $633.00M | +70.2% |
| Q1 FY2021 | Mar 31, 2021 | $761.00M | +192.7% |
| Q4 FY2020 | Dec 31, 2020 | $893.00M | +100.7% |
| Q3 FY2020 | Sep 30, 2020 | $807.00M | +104.3% |
| Q2 FY2020 | Jun 30, 2020 | $372.00M | -4.1% |
| Q1 FY2020 | Mar 31, 2020 | $260.00M | -21.7% |
| Q4 FY2019 | Dec 31, 2019 | $445.00M | +47.8% |
| Q3 FY2019 | Sep 30, 2019 | $395.00M | +3.7% |
| Q2 FY2019 | Jun 30, 2019 | $388.00M | +1.6% |
| Q1 FY2019 | Mar 31, 2019 | $332.00M | -4.0% |
| Q4 FY2018 | Dec 31, 2018 | $301.00M | -12.0% |
| Q3 FY2018 | Sep 30, 2018 | $381.00M | +3.8% |
| Q2 FY2018 | Jun 30, 2018 | $382.00M | -0.8% |
| Q1 FY2018 | Mar 31, 2018 | $346.00M | +1.5% |
| Q4 FY2017 | Dec 31, 2017 | $342.00M | +0.9% |
| Q3 FY2017 | Sep 30, 2017 | $367.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $385.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $341.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $339.00M | – |
See a number that looks wrong?